Throughout its history, Mylan has been recognized as a leader in the United States (“U.S.”) generic pharmaceutical industry. Our leadership position is the result of, among other factors, our ability to efficiently obtain Abbreviated New Drug Application (“ANDA”) approvals and our reliable high quality supply chain.
Company profile
Website
CEO
Heather M. Bresch
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Mylan Laboratories Inc
SEC CIK
Corporate docs
IRS number
251211621
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
6 May 22
EFFECT
Notice of effectiveness
29 Sep 21
424B3
Prospectus supplement
28 Sep 21
UPLOAD
Letter from SEC
17 Sep 21
EFFECT
Notice of effectiveness
12 Dec 18
424B3
Prospectus supplement
11 Dec 18
CORRESP
Correspondence with SEC
7 Dec 18
UPLOAD
Letter from SEC
20 Nov 18
Latest ownership filings
SC 13G
Mylan Inc.
12 Feb 15
SC 13G/A
Mylan Inc.
11 Feb 15
SC 13G/A
Mylan Inc.
15 Jan 15
SC 13G/A
Mylan Inc.
14 Feb 14
SC 13G/A
Mylan Inc.
11 Feb 14
SC 13G/A
Mylan Inc.
11 Feb 14
11-K
Annual report of employee stock purchases
20 Jun 12
11-K
Annual report of employee stock purchases
20 Jun 12
11-K
Annual report of employee stock purchases
24 Jun 11
11-K
Annual report of employee stock purchases
24 Jun 11
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|